中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.021 seconds)

    DYNAMIC ADJUSTMENT OF A CORRECTION FACTOR OF A USER BASED ON GLUCOSE VALUES
    1.
    发明申请
    DYNAMIC ADJUSTMENT OF A CORRECTION FACTOR OF A USER BASED ON GLUCOSE VALUES 有权

    公开(公告)号：US20250058042A1

    公开(公告)日：2025-02-20

    申请号：US18800698

    申请日：2024-08-12

    Applicant: INSULET CORPORATION

    Inventor： Joon Bok LEE ,  Yibin ZHENG ,  William WHITELEY ,  Jason O’CONNOR

    IPC: A61M5/142

    Abstract: The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

    THRESHOLD BASED AUTOMATIC GLUCOSE CONTROL RESPONSE
    7.
    发明申请
    THRESHOLD BASED AUTOMATIC GLUCOSE CONTROL RESPONSE 有权

    公开(公告)号：US20220379029A1

    公开(公告)日：2022-12-01

    申请号：US17824494

    申请日：2022-05-25

    Applicant: Insulet Corporation

    Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG

    IPC: A61M5/172 ,  G16H20/17 ,  A61B5/145 ,  A61B5/00 ,  G16H40/63 ,  A61M5/142

    Abstract: Provided is a wearable medical device that includes a processor or logic circuitry. The wearable medical device may include a memory storing instructions that, when executed by the processor or logic circuitry, configure the wearable medical device to determine, by the processor or the logic circuitry, that an event affecting a blood glucose measurement value trend of a user has occurred. Based on the occurrence of the event, the processor or the logic circuitry may select a mode of operation of the analyte sensor, and generate a signal indicating the selected mode of operation. The mode of operation may correspond to a sampling frequency of a physical attribute or physiological condition of a user of the wearable medical device.

    DEVICES AND METHODS FOR INITIALIZATION OF DRUG DELIVERY DEVICES USING MEASURED ANALYTE SENSOR INFORMATION
    8.
    发明申请
    DEVICES AND METHODS FOR INITIALIZATION OF DRUG DELIVERY DEVICES USING MEASURED ANALYTE SENSOR INFORMATION 有权

    公开(公告)号：US20220347386A1

    公开(公告)日：2022-11-03

    申请号：US17730839

    申请日：2022-04-27

    Applicant: Insulet Corporation

    Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG

    IPC: A61M5/172 ,  G16H20/13 ,  G16H20/17 ,  G16H40/67

    Abstract: Disclosed are processes and techniques implementable by a drug delivery system to maintain optimal drug delivery for a patient according to a treatment plan. The disclosed techniques enable a new drug delivery device that is exchanged for a previous drug delivery device to operate using analyte-based drug delivery control immediately during initialization instead of having to wait for a warm-up period. For example, a drug delivery device may include a processor and a memory storing instructions that, when executed by the processor, operate the drug delivery device to receive a present analyte measurement value from an analyte sensor during an initialization of the drug delivery device, receive backfill values measured by the analyte sensor prior to the initialization, calculate a dosage of a drug using the present analyte measurement value and the backfill values, and deliver the dosage of the drug. Other embodiments are described.

    ADAPTATION OF AUTOMATIC INSULIN DELIVERY (AID) FOR USERS WITH BASAL TO BOLUS MISMATCH
    9.
    发明申请
    ADAPTATION OF AUTOMATIC INSULIN DELIVERY (AID) FOR USERS WITH BASAL TO BOLUS MISMATCH 有权

    公开(公告)号：US20220280721A1

    公开(公告)日：2022-09-08

    申请号：US17684652

    申请日：2022-03-02

    Applicant: Insulet Corporation

    Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

    IPC: A61M5/172 ,  G16H20/17

    Abstract: Exemplary embodiments provide more customized basal insulin amounts for users to better regulate blood glucose (BG) concentration levels. The exemplary embodiments do not statically assume that the daily basal amount for each user is 50% of TDI. Instead, actual TDI data may be gathered for each user and may be used to adjust the TDI value for that user to an updated value. In addition, the ratio of basal to TDI may be adjusted for the user based on the actual ratio determined from data gathered over one or more days. As a result, better BG concentration level control may be realized.

    USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM
    10.
    发明申请
    USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM 有权

    公开(公告)号：US20210244881A1

    公开(公告)日：2021-08-12

    申请号：US16789051

    申请日：2020-02-12

    Applicant: Insulet Corporation

    Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

    IPC: A61M5/172 ,  A61K38/28 ,  A61M31/00 ,  G16H40/63

    Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

Patent Agency Ranking